DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
53	シェーグレン症候群	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03226444 (ClinicalTrials.gov)	June 30, 2017	19/7/2017	Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome	A Double-Masked, Randomized, Multi-Center Phase 2 Study to Evaluate the Efficacy and Safety of Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome	Primary Sjögren Syndrome;Dry Eye	Drug: 0.005% Lacripep;Drug: 0.01% Lacripep;Drug: Placebo	TearSolutions, Inc.	NULL	Completed	18 Years	N/A	All	204	Phase 1;Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03226444
(ClinicalTrials.gov)

June 30, 2017

19/7/2017

Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome

A Double-Masked, Randomized, Multi-Center Phase 2 Study to Evaluate the Efficacy and Safety of Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome

Primary Sjögren Syndrome;Dry Eye

Drug: 0.005% Lacripep;Drug: 0.01% Lacripep;Drug: Placebo

TearSolutions, Inc.

NULL

Completed

18 Years

N/A

All

204

Phase 1;Phase 2

United States